Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12621769 | 0.86 | ALDH1A1 (0.35) | ALDH1A1ATMMEN1CYP2C9CYP2C19 | |
| SCHEMBL13990342 | 0.78 | CHRM2 (0.36) | ALDH1A1ATMCHRM2CHRM3NEK2 | |
| SCHEMBL4903606 | 0.71 | CHRM2 (0.34) | ALDH1A1ATMMEN1CYP2C9CYP2C19 | |
| SCHEMBL12621779 | 0.70 | GRIN2D (0.33) | CHRM2 | |
| SCHEMBL4868611 | 0.68 | PIN1 (0.34) | ALDH1A1CHRM2CHRM3NEK2MAPK1 | |
| SCHEMBL12655738 | 0.67 | — | — | |
| SCHEMBL4872745 | 0.66 | PIN1 (0.48) | ALDH1A1ATMMEN1KMT2AMAPK1 | |
| SCHEMBL23159662 | 0.66 | ALDH1A1 (0.36) | ALDH1A1ATMMEN1CYP2C9CYP2C19 | |
| SCHEMBL16749609 | 0.66 | NEK2 (0.32) | NEK2 | |
| SCHEMBL15381287 | 0.64 | CHRM2 (0.34) | ALDH1A1CHRM2CHRM3NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10222368-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | BURNS BARBIER LINDSAY (US) | 2016-09-01 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | ALDH1A1 2575/4885ATM 4684/4885MEN1 3737/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | ALDH1A1 3552/4885ATM 3137/4885MEN1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.